Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy

2020 ◽  
Vol 142 ◽  
pp. 105136 ◽  
Author(s):  
Yuchi Wang ◽  
Zhiyong Luan ◽  
Chaoyue Zhao ◽  
Chunhua Bai ◽  
Kangjuan Yang
2020 ◽  
Vol 12 (37) ◽  
pp. 41138-41147
Author(s):  
Dongdong Wang ◽  
Conghui Liu ◽  
Shiquan You ◽  
Kai Zhang ◽  
Meng Li ◽  
...  

Pathogens ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 969
Author(s):  
Natasha Helleberg Madsen ◽  
Boye Schnack Nielsen ◽  
Son Ly Nhat ◽  
Søren Skov ◽  
Monika Gad ◽  
...  

Tumor-associated macrophages often correlate with tumor progression, and therapies targeting immune cells in tumors have emerged as promising treatments. To select effective therapies, we established an in vitro 3D multicellular spheroid model including cancer cells, fibroblasts, and monocytes. We analyzed monocyte infiltration and differentiation in spheroids generated from fibroblasts and either of the cancer cell lines MCF-7, HT-29, PANC-1, or MIA PaCa-2. Monocytes rapidly infiltrated spheroids and differentiated into mature macrophages with diverse phenotypes in a cancer cell line-dependent manner. MIA PaCa-2 spheroids polarized infiltrating monocytes to M2-like macrophages with high CD206 and CD14 expression, whereas monocytes polarized by MCF-7 spheroids displayed an M1-like phenotype. Monocytes in HT-29 and PANC-1 primarily obtained an M2-like phenotype but also showed upregulation of M1 markers. Analysis of the secretion of 43 soluble factors demonstrated that the cytokine profile between spheroid cultures differed considerably depending on the cancer cell line. Secretion of most of the cytokines increased upon the addition of monocytes resulting in a more inflammatory and pro-tumorigenic environment. These multicellular spheroids can be used to recapitulate the tumor microenvironment and the phenotype of tumor-associated macrophages in vitro and provide more realistic 3D cancer models allowing the in vitro screening of immunotherapeutic compounds.


Nano Letters ◽  
2021 ◽  
Author(s):  
Xiang Xiong ◽  
Jingya Zhao ◽  
Jingmei Pan ◽  
Chunping Liu ◽  
Xing Guo ◽  
...  

ACS Nano ◽  
2011 ◽  
Vol 5 (5) ◽  
pp. 3516-3522 ◽  
Author(s):  
Suzana P. Nunes ◽  
Ali Reza Behzad ◽  
Bobby Hooghan ◽  
Rachid Sougrat ◽  
Madhavan Karunakaran ◽  
...  

2019 ◽  
Vol 16 (5) ◽  
pp. 2249-2258 ◽  
Author(s):  
Xinlong Zang ◽  
Xiaoxu Zhang ◽  
Haiyang Hu ◽  
Mingxi Qiao ◽  
Xiuli Zhao ◽  
...  

Nanomaterials ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 1613
Author(s):  
Yunfeng Yan ◽  
Hangwei Ding

Immunotherapy has recently become a promising strategy for the treatment of a wide range of cancers. However, the broad implementation of cancer immunotherapy suffers from inadequate efficacy and toxic side effects. Integrating pH-responsive nanoparticles into immunotherapy is a powerful approach to tackle these challenges because they are able to target the tumor tissues and organelles of antigen-presenting cells (APCs) which have a characteristic acidic microenvironment. The spatiotemporal control of immunotherapeutic drugs using pH-responsive nanoparticles endows cancer immunotherapy with enhanced antitumor immunity and reduced off-tumor immunity. In this review, we first discuss the cancer-immunity circle and how nanoparticles can modulate the key steps in this circle. Then, we highlight the recent advances in cancer immunotherapy with pH-responsive nanoparticles and discuss the perspective for this emerging area.


Sign in / Sign up

Export Citation Format

Share Document